Guardant Health, Inc.

Public Equity (NASDAQ)Precision OncologyGenomicsPublic Company

📍 Palo Alto, CA, United States• Founded 2012

StreetZero Signal 51

Be the first to signal interest

About Guardant Health, Inc.

Guardant Health, Inc. is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Founded in 2012 in Palo Alto, California, Guardant is transforming patient care and accelerating new cancer therapies by providing critical genomic insights. The company has raised approximately $550 million in funding in its first six years and went public on NASDAQ under ticker GH.

LATEST FUNDINGRule 144

$19K

Announced 2026-10-16

TOTAL RAISED$557M

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Guardant Health, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES—

FOUNDED2012

HQPalo Alto, CA, United States

Industry

Public Equity (NASDAQ)

Investors

Sequoia Capital Lightspeed Venture Partners SoftBank Vision Fund Khosla Ventures OrbiMed 8VC

Key highlights

Raised $557M total across 7 rounds with institutional backers including Sequoia and SoftBank Vision Fund.
Completed IPO in 2018 at $19 per share raising $237.5M gross proceeds.
Focuses on proprietary blood tests and digital sequencing for cancer detection and therapy acceleration.
Announced multiple post-IPO equity offerings including a $350M round in 2025.
Aims to sequence DNA of one million cancer patients over five years.